For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required. Interest/expertise in investigational new drugs, symptom science/supportive care, patient reported outcomes, application of real world evidence and clinical trials is desirable but not required. As one of our Senior Investigators you will be co-principal investigator of individual trials, and leader within the CCTG program and the CCTG scientific committees.
Everyone at CCTG would like to congratulate Dr Frances Shepherd who was recently awarded the Lifetime Contribution Prize from the Canadian Cancer Society. She is an international leader in clinical and translational lung cancer research whose work has transformed the standard of care for patients in Canada and around the world.
Congratulations to Dr. Philippe Bedard who was recently honoured with the 17th annual Michaele C. Christian Oncology Drug Development Award at the NCI CTEP Early Drug Development Meeting.
Researchers are leveraging new technology to identify tiny amounts of cancer cell DNA in the blood (circulating tumour DNA – ctDNA) as an indicator of the presence of otherwise undetectable numbers of residual colon cancer cells after surgical removal of the main tumour.
CCTG is still accepting members for our Equity, Diversity, Inclusivity, Indigenization, Accessibility (EDIIA) Working Groups as we strive to create a more equitable, diverse, inclusive, accessible, and culturally safe community for our network and for our patient participants.
